Five-Year Outcome of the Venovo Venous Stent for the Treatment of Iliac Vein Compression: Results from a Single Center

Abstract

The Venovo self-expanding venous stent (Bard/BD, New Jersey, United States) is approved for the treatment of symptomatic iliofemoral venous obstruction and demonstrated excellent 3-year outcomes in the pivotal VERNACULAR trial. Long-term (>3-year) data remain limited. This retrospective, single-center study evaluated 50 consecutive patients who completed 5-year follow-up after receiving the Venovo stent for symptomatic iliac vein compression. Data were extracted from medical records following approval by a central ethics committee. Of the 50 patients, 6 died and 1 was lost to follow-up. The primary endpoint was major adverse events at 5 years, including target lesion revascularization (TLR), target vessel revascularization (TVR), and mortality. Secondary analyses assessed changes in CEAP class, edema, and active ulceration compared with baseline. No TLR or TVR occurred during the 5-year follow-up. Six deaths were observed, none procedural or device-related. Overall survival was 87.8%. Duplex ultrasound demonstrated 100% patency. CEAP class significantly improved from baseline to 5 years (p = 0.0011), driven primarily by reduced edema and ulcer resolution. The Venovo venous stent demonstrated excellent long-term safety with 100% patency and no TLR at 5 years. Clinical improvement, including reduced edema and sustained ulcer healing, persisted throughout follow-up.

Keywords

Venovo stent - long-term outcome - target lesion revascularization - mortality - patency - CEAP class - edema

Note

Abstract was presented at Cardiovascular Innovations 2025, Austin, Texas, United States, July 24 to 26 and the International College of Angiology, Nashville, Tennessee, United States, November 2025.

Publication History

Received: 23 December 2025

Accepted: 12 January 2026

Article published online:
02 February 2026

• References

• 1 Radaideh Q, Patel NM, Shammas NW. Iliac vein compression: epidemiology, diagnosis and treatment. Vasc Health Risk Manag 2019; 15: 115-122
• 2 Shammas NW, Radaideh Q, Shammas G. et al. Venovo venous stent in treating iliac vein compression: a single-center experience. J Invasive Cardiol 2021; 33 (09) E677-E680
• 3 Dake MD, O'Sullivan G, Shammas NW, Lichtenberg M, Mwipatayi BP, Settlage RA. Vernacular Trial Investigators. Three-year results from the venovo venous stent study for the treatment of iliac and femoral vein obstruction. Cardiovasc Intervent Radiol 2021; 44 (12) 1918-1929
• 4 Jiang L, Zhuang H, Song T, Li X-Q. Clinical outcomes at 3 years after stenting for thrombotic and non-thrombotic iliac vein compression syndrome patients. Clin Appl Thromb Hemost 2024; 30: 10 760296231220053
• 5 Desai KR, Sabri SS, Elias S. et al. Consensus statement on the management of nonthrombotic iliac vein lesions from the VIVA Foundation, the American Venous Forum, and the American Vein and Lymphatic Society. Circ Cardiovasc Interv 2024; 17 (08) e014160
• 6 Shammas NW, Shammas GA, Jones-Miller S. et al. Predicting iliac vein compression with computed tomography angiography and venography: correlation with intravascular ultrasound. J Invasive Cardiol 2018; 30 (12) 452-455
• 7 Bashar K, Shalan A, Sharafat Ali S, Tang T, Tiwari A. Endovascular versus medical treatment of venous compression syndrome of the iliac vein - a systematic review. Vasa 2021; 50 (01) 22-29
• 8 Pantoja JL, Patel RP, Ulloa JG, Farley SM. Deep venous stenting improves healing of lower extremity venous ulcers. Ann Vasc Surg 2022; 78: 239-246